OICR spins offs to develop promising technologies

The Ontario Institute for Cancer Research (OICR) has spun off three companies to move anticancer technologies to market. The undisclosed investments follow seed funding provided through its Intellectual Property Development and Commercialization program. The new companies are: DLVR Therapeutics Inc, which is developing a nanoparticle delivery system for anticancer therapies; Harmonic Medical Inc, which uses image-guided ultrasound surgery technologies to target and destroy targeted cancer sites; and, TORCell Therapeutics Inc, which uses proprietary immunotherapy to treat acute myeloid leukemia….